[{"address1": "3891 Ranchero Drive", "address2": "Suite 150", "city": "Ann Arbor", "state": "MI", "zip": "48108", "country": "United States", "phone": "734 887 3903", "website": "https://www.esperion.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.", "fullTimeEmployees": 240, "companyOfficers": [{"maxAge": 1, "name": "Mr. Sheldon L. Koenig", "age": 57, "title": "President, CEO & Director", "yearBorn": 1966, "fiscalYear": 2022, "totalPay": 1197433, "exercisedValue": 0, "unexercisedValue": 137453}, {"maxAge": 1, "name": "Mr. Benjamin O. Looker", "age": 41, "title": "General Counsel", "yearBorn": 1982, "fiscalYear": 2022, "totalPay": 550350, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. JoAnne Micale Foody FACC, M.D.", "age": 57, "title": "Chief Medical Officer", "yearBorn": 1966, "fiscalYear": 2022, "totalPay": 771191, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Benjamin  Halladay M.B.A.", "age": 37, "title": "Chief Financial Officer", "yearBorn": 1986, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Glenn P. Brame", "age": 65, "title": "Chief Technical Operations Officer", "yearBorn": 1958, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Tiffany  Aldrich M.B.A.", "title": "Associate Director of Corporate Communications", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Betty Jean Swartz", "title": "Chief Business Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Eric J. Warren R.Ph.", "age": 51, "title": "Chief Commercial Officer", "yearBorn": 1972, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 4, "boardRisk": 5, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1709251200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.68, "open": 2.7, "dayLow": 2.63, "dayHigh": 2.875, "regularMarketPreviousClose": 2.68, "regularMarketOpen": 2.7, "regularMarketDayLow": 2.63, "regularMarketDayHigh": 2.875, "beta": 0.82, "forwardPE": 55.8, "volume": 6533957, "regularMarketVolume": 6533957, "averageVolume": 6477423, "averageVolume10days": 9971638, "averageDailyVolume10Day": 9971638, "marketCap": 516297856, "fiftyTwoWeekLow": 0.7, "fiftyTwoWeekHigh": 3.335, "priceToSalesTrailing12Months": 4.438065, "fiftyDayAverage": 2.405, "twoHundredDayAverage": 1.7364995, "currency": "USD", "enterpriseValue": 943537088, "profitMargins": -1.79868, "floatShares": 183650005, "sharesOutstanding": 185052992, "sharesShort": 17665969, "sharesShortPriorMonth": 18569333, "sharesShortPreviousMonthDate": 1707955200, "dateShortInterest": 1710460800, "sharesPercentSharesOut": 0.0955, "heldPercentInsiders": 0.00803, "heldPercentInstitutions": 0.41691002, "shortRatio": 4.07, "shortPercentOfFloat": 0.1066, "impliedSharesOutstanding": 185052992, "bookValue": -3.849, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -209248000, "trailingEps": -2.03, "forwardEps": 0.05, "pegRatio": -0.4, "enterpriseToRevenue": 8.111, "enterpriseToEbitda": -6.072, "52WeekChange": 1.0364964, "SandP52WeekChange": 0.28136122, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "ESPR", "underlyingSymbol": "ESPR", "shortName": "Esperion Therapeutics, Inc.", "longName": "Esperion Therapeutics, Inc.", "firstTradeDateEpochUtc": 1372253400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "00314c6d-38c1-3c8e-a318-bd51d9ba1c8c", "messageBoardId": "finmb_28236", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.79, "targetHighPrice": 16.0, "targetLowPrice": 2.9, "targetMeanPrice": 7.41, "targetMedianPrice": 8.0, "recommendationMean": 2.1, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 82248000, "totalCashPerShare": 0.444, "ebitda": -155399008, "totalDebt": 540947008, "quickRatio": 0.837, "currentRatio": 1.287, "totalRevenue": 116334000, "revenuePerShare": 1.128, "returnOnAssets": -0.42856, "freeCashflow": -107141872, "operatingCashflow": -135487008, "revenueGrowth": 0.714, "grossMargins": -0.11209, "ebitdaMargins": -1.3358, "operatingMargins": -1.31371, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-02"}]